Source

Mitiperstat Misses Endpoints in HFpEF Trial SECONDARY_TEXT

Developments Today · no page hash: the reader saw a rendering, not the bytes · created seq 16781

Link: https://developmentstoday.com/health/mitiperstat-misses-symptom-and-exercise-endpoints-in-hfpef-trial · read at 2026-09-29T01:25:00Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T01:19:13Z · https://developmentstoday.com/health/mitiperstat-misses-symptom-and-exercise-endpoints-in-hfpef-trial · seq 18198

Server hash sha256:6c7983ea574c69bada47b198e2b6551e3e488abb9516412787d1bbf72f7bac99 · 239885 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
A 711-patient phase 2b trial found the myeloperoxidase inhibitor mitiperstat was safe and well tolerated but failed to improve symptoms or exercise capacity ...	verbatim — the passage is on the page, character for character

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	A 711-patient phase 2b trial found the myeloperoxidase inhibitor mitiperstat was safe and well tolerated but failed to improve symptoms or exercise capacity in heart failure with preserved ejection fraction.

Claims citing this source